Skip to main content
  • AHA: Post-CABG Ticagrelor No Better Than Aspirin

    And safety no better with ticagrelor either

    CHICAGO -- Ticagrelor (Brilinta) alone failed to reduce rates of both major adverse cardiovascular events (MACE) and major bleeding compared with aspirin in patients who underwent coronary artery bypass grafting (CABG), the phase III TiCAB trial found.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details